SWTX250509P46000
- 0.50
- 0.000.00%
SpringWorks Therapeutics Newsroom
H.C. Wainwright Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
SpringWorks Therapeutics Analyst Ratings
HC Wainwright & Co. Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47
Hold Rating Issued Amid Concerns Over Merck's Acquisition of SpringWorks Therapeutics
TD Cowen Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Hold Rating, Maintains Target Price $47
Guggenheim Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
Guggenheim Downgrades Springworks Therapeutics to Neutral From Buy, Adjusts Price Target to $47 From $77
TD Cowen Downgrades Springworks Therapeutics to Hold From Buy, Adjusts Price Target to $47 From $66
SpringWorks Therapeutics Analyst Ratings
H.C. Wainwright Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $74
Barclays Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
Evercore Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
Barclays Downgrades Springworks Therapeutics to Equalweight From Overweight, Price Target Is $47
SpringWorks Therapeutics Downgraded to In Line From Outperform at Evercore ISI
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
Evercore Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $65
BofA Securities Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Cuts Target Price to $84
BofA Adjusts Price Target on Springworks Therapeutics to $84 From $87, Keeps Buy Rating
Springworks Therapeutics (SWTX) Receives a Buy From Bank of America Securities